Pharming Group’s facilities for the manufacture of Rhucin have passed all EMEA inspections, establishing GMP compliance for pharmaceutical production. The EMEA has confirmed that all facilities and processes involved in the manufacture of Rhucin, Pharming’s lead product, operate according to GMP standards. These include facilities for transgenic rabbits, the external facilities where milk and product are processed, and the company’s headquarters in Leiden, in relation with qual...